Upregulation of calpastatin in regenerating and developing rat liver: Role in resistance against hepatotoxicity

Hepatology

Volumn 44, Issue 2, 2006, Pages 379-388

  Limaye, Pallavi B ^a   Bhave, Vishakha S ^a   Palkar, Prajakta S ^a   Apte, Udayan M ^a   Sawant, Sharmilee P ^a   Yu, Songtao ^b   Latendresse, John R ^c   Reddy, Janardan K ^b   Mehendale, Harihara M ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN; CALPASTATIN; CARBON TETRACHLORIDE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; FODRIN; PARACETAMOL;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIVISION; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; COVALENT BOND; CYTOPLASM; DISEASE COURSE; DRUG OVERDOSE; IMMUNOHISTOCHEMISTRY; LETHAL DOSE; LIVER DEVELOPMENT; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER REGENERATION; LIVER RESECTION; LIVER TOXICITY; MALE; METABOLITE; MOUSE; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TISSUE REPAIR; UPREGULATION;

ACETAMINOPHEN; ANIMALS; ANIMALS, NEWBORN; CALCIUM-BINDING PROTEINS; CALPAIN; CARBON TETRACHLORIDE; CELL DIVISION; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; LIVER; LIVER FAILURE, ACUTE; LIVER REGENERATION; MALE; MICE; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; UP-REGULATION;

EID: 33747036972     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21250     Document Type: Article

References (49)

1. Lee WM. Acetaminophen and the U.S. acute liver failure study group: Lowering the risks of hepatic failure. HEPATOLOGY 2004;40:6-9.
2. McGregor AH, More LJ, Simpson KJ, Harrison DJ. Liver death and regeneration in paracetamol toxicity. Hum Exp Toxicol 2003;22:221-227.
3. Hughes RD, Zhang L, Tsubouchi H, Daikuhara Y, Williams R. Plasma hepatocyte growth factor and biliprotein levels and outcome in fulminant hepatic failure. J Hepatol 1994;20:106-111.
4. Mehendale HM. Amplified interactive toxicity of chemicals at nontoxic levels: mechanistic considerations and implications to public health. Environ Health Perspect 1994;102:139-149.
5. Horn KD, Wax P, Schneider SM, Martin TG, Nine JS, Moraca MA, et al. Biomarkers of liver regeneration allow early prediction of hepatic recovery after acute necrosis. Am J Clin Pathol 1999;112:351-357.
6. Shayiq RM, Roberts DW, Rothstein K, Snawder JE, Benson W, Ma X, et al. Repeated exposure to incremental dose of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. HEPATOLOGY 1999;29:451-463.
7. Dalhoff K, Laursen H, Bangert K, Puolsen HE, Anderson ME, Grunnet N, et al. Autoprotection in acetaminophen intoxication in rats: the role of liver regeneration. Pharmacol Toxicol 2001;88:135-141.
8. Uryvaeva IV, Faktor VM. Resistance of regenerating liver to hepatotoxins. Biull Eksp Biol Med 1976;81:283-285.
9. Mangipudy RS, Chanda S, Mehendale HM Hepatocellular regeneration: key to thioacetamide autoprotection. Pharmacol Toxicol 1995;77:182-188.
10. Chanda S, Mangipudy RS, Warbritton A, Bucci TJ, Mehendale HM. Stimulated hepatic tissue repair underlies heteroprotection by thioacetamide against acetaminophen-induced lethality. HEPATOLOGY 1995;21:477-486.
11. Nayak NC, Chopra P, Dhar A, Das PK. Diverse mechanisms of hepatocellular injuries due to chemicals: evidence in rats administered carbon tetrachloride or dimethylnitrosamine. Br J Exp Pathol 1975;56:103-112.
12. Bell AN, Young RA, Lockard VG, Mehendale HM. Protection of chlordecone-potentiated carbon tetrachloride hepatotoxicity and lethality by partial hepatectomy. Arch Toxicol 1988;61:392-405.
13. 4 by partial hepatectomy. Toxicol Pathol 1989;17:494-505.
14. Zhang BH, Gong DZ, Mei MH. Protection of regenerating liver after partial hepatectomy from carbon tetrachloride hepatotoxicity in rats: role of hepatic stimulator substance. J Gastroenterol Hepatol 1999;14:1010-1017.
15. Cai Z, Mehendale HM. Resiliency to amplification of carbon tetrachloride hepatotoxicity by chlordecone during postnatal development in rats. Pediatr Res 1993;33:225-232.
16. 4 hepatotoxicity. Toxicology 1996;111:29-42.
17. Sanz N, Diez-Fernandez C, Fernandez-Simon L, Alvarez A, Cascales M. Necrogenic and regenerative responses of liver of newly weaned rats against a sublethal dose of thioacetamide. Biochim Biophys Acta 1998;1384:66-78.
18. Roberts E, Ahluwalia M, Lee G, Chan C, Satma D, Farber E. Resistance to hepatotoxins acquired by hepatocytes during liver regeneration. Cancer Res 1983;43:28-34.
19. Ruch RJ, Klaunig JE, Pereira MA. Selective resistance to cytotoxic agents in hepatocytes isolated from partially hepatectomized and neoplastic mouse liver. Cancer Lett 1985;26:295-301.
20. Mehendale HM. Role of hepatocellular regeneration and hepatolobular healing in the final outcome of liver injury: a two-stage model of toxicity. Biochem Pharmacol 1991;42:1155-1162.
21. Mehendale HM. Tissue repair: an important determinant of final outcome of toxicant-induced injury. Toxicol Pathol 2005;33:41-51.
22. Limaye PB, Apte UM, Shankar K, Bucci TJ, Warbritton A, Mehendale HM. Calpain released from dying hepatocytes mediates progression of acute liver injury induced by model hepatotoxicants. Toxicol Appl Pharmacol 2003;191:211-226.
23. Di Rosa G, Odrijin T, Nixon RA, Arancio O. Calpain inhibitors: a treatment for Alzheimer's disease. J Mol Neurosci 2002;19:135-141.
24. Rami A, Krieglstein J. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res 1993;609:67-70.
25. Wang KK, Yuen PW. Development and therapeutic potential of calpain inhibitors. Adv Pharmacol 1997;37:117-152.
26. David LL, Shearer TR. Role of proteolysis in lenses: a review. Lens Eye Toxic Res 1989;6:725-747.
27. Kohli V, Madden JF, Bentley RC, Clavien PA. Calpain mediates ischemic injury of the liver through modulation of apoptosis and necrosis. Gastroenterology 1999;116:168-178.
28. Shi Y, Melnikov VY, Schrier RW, Edelstein CL. Downregulation of the calpain inhibitor protein calpastatin by caspases during renal ischemia-reperfusion. Am J Physiol Renal Physiol 2000;279:F509-F517.
29. Schnellmann RG, Williams SW. Proteases in renal cell death: calpains mediate cell death produced by diverse toxicants. Ren Fail 1998;20:679-686.
30. Johnson P, Hammer JL. Calpain and calpastatin levels in dystrophic hamster skeletal muscles. Int J Biochem 1988;20:1227-1230.
31. Saido TC, Kawashima S, Tani E, Yokota M. Up- and down-regulation of calpain inhibitor polypeptide, calpastatin, in postischemic hippocampus. Neurosci Lett 1997;227:75-78.
32. Huang J, Forsberg NE. Role of calpain in skeletal-muscle protein degradation. Proc Natl Acad Sci USA 1998;95:12100-12105.
33. Sedarous M, Keramaris E, O'Hare M, Melloni E, Slack RS, Elce JS, et al. Calpains mediate p53 activation and neuronal death evoked by DNA damage. J Biol Chem 2003;278:26031-26038.
34. Maekawa A, Lee JK, Nagaya T, Kamiya K, Yasui K, Horiba M, et al. Overexpression of calpastatin by gene transfer prevents troponin I degradation and ameliorates contractile dysfunction in rat hearts subjected to ischemia/reperfusion. J Mol Cell Cardiol 2003;35:1277-1284.
35. 2+-dependent neutral protease in rat liver. J Biochem (Tokyo) 1978;84:1657-1659.
36. Waxman L, Krebs EG. Identification of two protease inhibitors from bovine cardiac muscle. J Biol Chem 1978;253:5888-5891.
37. Suzuki K, Imajoh S, Emori Y, Kawasaki H, Minami Y, Ohno S. Calcium-activated neutral protease and its endogenous inhibitor: activation at the cell membrane and biological function. FEBS Lett 1987;220:271-277.
38. Inomata M, Kasai Y, Nakamura M, Kawashima S. Activation mechanism of calcium-activated neutral protease: evidence for the existence of intramolecular and intermolecular autolyses. J Biol Chem 1988;263:19783-19787.
39. McClelland P, Hathaway DR. The calpain-calpastatin system in vascular smooth muscle. FEBS Lett 1991;290:55-57.
40. Takano E, Maki M. Calpastatin: molecular mechanism of calpain inhibition. Tanpakushitsu Kakusan Koso 1997;42:2181-2188.
41. Adachi Y, Ishida-Takahashi A, Takahashi C, Takano E, Murachi T, Hatanaka M. Phosphorylation and subcellular distribution of calpastatin in human hematopoietic system cells. J Biol Chem 1991;266:3968-3972.
42. Lane RD, Allan DM, Mellgren RL. A comparison of the intracellular distribution of mu-calpain, m-calpain, and calpastatin in proliferating human A431 cells. Exp Cell Res 1992;203:5-16.
43. 4 hepatotoxicity: a novel dose-response. Toxicology 1997;118:181-193.
44. Higgins GM, Anderson RM. Experimental pathology of the liver. I. Restoration of the liver of the white rat following partial surgical removal. Arch Pathol 1934;12:186-202.
45. Koop DR. Hydroxylation of p-nitrophenol by rabbit ethanol-inducible cytochrome P-450 isozyme 3a. Mol Pharmacol 1986;29:399-404.
46. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-2514.
47. Mitchell KO, El-Deiry WS. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ 1999;10:223-230.
48. Mehendale HM, Limaye PB. Calpain: a death protein that mediates progression of liver injury. Trends Pharmacol Sci 2005;26:232-236.
49. Wingrave JM, Sribnick EA, Wilford GG, Matzelle DD, Mou JA, Ray SK, et al. Higher calpastatin levels correlate with resistance to calpain-mediated proteolysis and neuronal apoptosis in juvenile rats after spinal cord injury. J Neurotrauma 2004;21:1240-1254.